Brookfield Asset Management and Warburg Pincus closed the month's largest deals, lifting global private equity and venture capital transaction value to $43.31 billion in July — the second consecutive monthly increase and the strongest print since October. The figure marks a 37% lift from June's $31.6 billion and sits 19% above the twelve-month trailing average of $36.4 billion. Brookfield anchored infrastructure appetite with a $7.2 billion take-private of a European renewables platform, while Warburg Pincus led a $4.8 billion buyout consortium targeting enterprise software in the healthcare vertical. The two deals alone accounted for 28% of July volume.

The month's acceleration reflects deployment discipline loosening after five quarters of muted activity. Dry powder in North American buyout funds sits at $1.13 trillion, unchanged from Q1 but rotating faster as managers mark down 2021 vintage assets and clear portfolio space. Exit volume rose in parallel: July secondaries and sponsor-to-sponsor transfers hit $18.7 billion, up 41% month-over-month, signaling that capital is cycling rather than sitting. Warburg's move into healthcare IT aligns with the firm's $3.2 billion SaaS fund raised in Q2, now 63% deployed within ninety days — a pace not seen since late 2021.

The surge matters less for its size than its composition. Brookfield's infrastructure deal priced at 11.2x forward EBITDA, a 140 basis point discount to the sector's 2022 peak but still 80 basis points rich to the five-year median. The bid reflects conviction that regulated renewables cash flows will tighten spreads as real rates stabilize. Warburg's healthcare software target carried 28% recurring revenue and 41% EBITDA margins — the profile that has underwritten every mega-buyout this year. Allocators reading the tape should note that both deals closed with sub-50% leverage, implying sponsors are prioritizing equity checks over structure. That conservatism will compress IRRs but extends hold periods, reshaping the 2027-2029 exit calendar.

Watch three follow-on signals. First, Brookfield has $12.8 billion in unallocated infrastructure capital; another European renewables platform is under exclusivity with expected close in Q4. Second, Warburg's healthcare fund holds $1.18 billion in dry powder and is circling two more vertical SaaS targets, one in pharma supply chain, another in diagnostics middleware. Third, secondary pricing improved 220 basis points in July to 87 cents on NAV, the tightest discount since March 2022. If that holds through August, expect another $15-20 billion in sponsor-to-sponsor volume as 2019-2020 vintage funds force exits to return capital.

The July print is not a turning point. It is confirmation that managers with sector conviction and balance sheet discipline are moving capital while others wait for the Fed's September decision. Brookfield and Warburg are not calling a bottom — they are pricing specific cash flows at specific multiples. The market is watching to see if others follow or if August reverts to the mean.